ALNYAlnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics, a drug modality designed to silence disease-causing genes at the messenger RNA level. Alnylam Pharmaceuticals develops and commercializes medicines for rare and genetically defined diseases, with current products addressing transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1. Its marketed portfolio includes therapies used in specialty care settings across neurology, cardiology, hepatology, and metabolic disease, supported by a broader pipeline in cardiovascular, neuroscience, hepatic, and other disease areas. The company operates as a global commercial-stage organization, combining proprietary RNAi science with manufacturing, regulatory, and commercial capabilities to bring targeted treatments to patients and healthcare providers.